Ensysce Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders held on January 7, 2026. The filing was submitted on January 8, 2026, by Ensysce Biosciences, Inc., a Delaware corporation trading on The Nasdaq Stock Market under the symbol ENSC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Four proposals were submitted to a vote at the Annual Meeting, and all were approved by stockholders:
- Equity Issuance Approval: Stockholders approved the full issuance of common stock and exercise of warrants to an investor to comply with Nasdaq Listing Rule 5635(d). The vote was 541,882 For, 195,475 Against, and 1,970 Abstentions.
- Equity Incentive Plan Amendment: Stockholders approved an amendment to the 2021 Omnibus Incentive Plan, increasing the aggregate number of shares available for issuance from 121,457 to 721,457. The vote was 439,446 For, 297,044 Against, and 2,837 Abstentions.
- Director Elections: Two Class I Directors were elected for terms expiring at the 2028 annual meeting:
- William Chang: 518,597 For, 220,730 Against.
- Lee Rauch: 516,907 For, 222,420 Against.
- Auditor Ratification: Stockholders ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The vote was 1,659,662 For, 105,399 Against, and 4,806 Abstentions.
A fifth proposal regarding the discretion to adjourn the meeting to solicit additional proxies was not submitted to a vote.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the specific terms and valuation of the equity issuance approved under Proposal 1.
- Confirm the impact of the 600,000 share increase in the 2021 Omnibus Incentive Plan on potential future dilution.
- Review the full proxy statement for details on the background of the elected directors and the rationale for the auditor selection.
- Note the significant number of broker non-votes (1,030,540) recorded across the proposals, indicating shares held by brokers that were not voted on discretionary matters.